Introduction
We c an measure a variety of appropriate lipids in the blood stream of patients and we know the ac c urac y and prec ision with whic h we c an do this. But it would be a waste of time and effort and money if we merely c hased more ac c urate and more prec ise assays, if the results of these assays did not also benefit the patients from whom the samples had been taken. The aim of this lec ture is to show that identifying those at risk of c ardiovasc ular disease by means of good analytic al methodology does indic ate a variety of treatments that c an be offered to the patients and that that treatment does benefit their c ardiovasc ular risk. There are long-term studies that show that this is true on a statistic al basis and these results will be referred to. But the emphasis of the lec ture is to show the help that has been given to individual patients bec ause of the hard work that has been done in c linic al c hemistry laboratories
H ypertriglyceridemia and CH D risk
There is some evidenc e for a role of triglyc eride in the development of CHD:
• fasting serum TG c onc entration is an independent risk fac tor in epidemiologic studies
• direc t role of TG-ric h lipoproteins in atherogenesis • assoc iation with other abnormalities of lipid and c arbohydrate metabolism
• assoc iation with hyperc oagulability TG elevation is generally assoc iated with inc reased risk for CHD on univariate analysis. Is the relation c ausal? Or is the TG elevation simply a marker for CHD risk through its assoc iations with suc h c onditions as type II diabetes mellitus, low HDL-C, and obesity? The TG-CHD relation tends to weaken or disappear on multivariate analysis.
There are also a number of assoc iated abnormalities that c ould play a role in making triglyc eride a c ardio-vasc ular risk fac tor. These are listed in 
Initial investigations of the patient
The first stage in dealing with an individual patient is to assess the degree of c ardiovasc ular risk of that partic ular patient.
Perhaps I should first of all try to modify some widely held views. On the one hand, although we c an quite easily c alc ulate a normal range of sodium or potassium, there is no suc h thing as a normal range for c holesterol. The sodium or potassium normal ranges are c alc ulated statistic ally from the general healthy population. But in Western Europe and the United States a c alc ulation of the upper limit of the total c holesterol normal range by suc h statistic al methods shows that the 9 5 th perc entile is sometimes quite a high level, one whic h is generally agreed to be unhealthy.
A recent meta-analysis of 38 trials demonstrated that for every 10% reduction in TC
• CHD mortality decreased by 15% (P<0.001)
• total mortality decreased by 11% (P<0.001)
Decreases were similar for all treatment modalities
Cholesterol reduction did not increase non-CHD mortality On the other hand, it is not helpful to identify a partic ular c holesterol level below whic h the risk is ac c eptable and above whic h the risk is inc reased. Thus, a c holesterol level whic h, in a young adult who exerc ises well, has no family history, and has a good HDL c onc entration, may be perfec tly ac c eptable for that individual, at least for the time being, but might be dangerous in an older patient with a strong family history, and previous c ardiovasc ular problems who lives a sedentary life and who has a very low HDL c holesterol level. The former patient may require treatment in due c ourse, but it is to no-one's benefit to jump in immediately and proffer lifelong treatment with hypolipidaemic drugs. It is therefore nec essary to assess every individual patient and to ask questions about their family history of c ardiovasc ular disease, their personal c ardiovasc ular history, to find out what their blood pressure is, whether they smoke ( and how muc h) , are they overweight, do they drink exc ess alc ohol, do they have an unhealthy diet, and to look in detail at various aspec ts of their lipid profile and their lifestyle.
From_ these fac tors an overall c ardiovasc ular risk c an be c alc ulated and those with a high c ardiovasc ular risk c an be treated without delay, but those without suc h a risk need not be immediately treated despite having a c holesterol level whic h is above a c ertain value.
Sec ondly, it is important to asc ertain whether the hyperlipidaemia is a primary c ondition or sec ondary to some other medic al c ondition. In partic ular, hypothyroidism, diabetes or alc oholism c an c ause inc reases in blood lipids levels whic h, if looked at on their own would suggest that treatment should be immediately instituted. However, it is preferable to treat the hypothyroidism, the diabetes, or even the alc oholism, to see if the c ardiovasc ular risk assoc iated with the lipid profile improved signific antly when these treatments are instituted.
Finally, every patient must be treated as an individual and the whole of his or her c ardiovasc ular risk profile must be assessed, together with that of any other primary c ause of the hyperlipidaemia.
In those with a high c ardiovasc ular risk it is usually essential to start treating with hypolipidaemic drug treatment as soon as possible but in those whose c ardiovasc ular risk is less serious, it is often helpful to try and c hange the patient's lifestyle to something whic h is more healthy and whic h c hange will itself improve the lipid profile and c ardiovasc ular risk. Thus, a patient with a very high c holesterol will require drug treatment without delay, whether or not there are other fac tors that inc rease the c ardiovasc ular risk. But if the c holesterol is only mildly raised, then time c an be taken to attempt lifestyles c hanges before c onsidering seriously the need for hypolipidaemic drug treatment. Suc h lifestyle c hanges inc lude c hanges in diet, inc rease in exerc ise, weight loss and c essation of smoking. Perhaps it should also be pointed out that many patients dislike the idea of having to take drugs that are absorbed into their blood system and have spec ific effec ts on their liver, partic ularly if, as in the c ase of hypolipidaemic drugs, these have to be taken virtually for the rest of their life.
Examples of suc c essful lifestyle c hanges are given in the following tables. 
Drug T reatment
There are three major types of drug treatment that have been shown to be effec tive ( 2 ) .
Bile-acid binding Resins
These resins are taken orally with food and pass through the gastrointestinal trac t without being absorbed into the blood stream. Some patients see this as an advantage. During its passage through the small intestine the Resin is able to absorb bile ac ids that are sec reted by the bile duc t into the duodenum. Approximately 2 0 -3 0 g. of bile ac ids per day are sec reted into the duodenum and then reabsorbed further down the small intestine. If these bile ac ids are unable to be re-absorbed bec ause they are bound to resins, then up to 3 0 g per day of bile ac ids ( and henc e c holesterol) are lost to the body. Also the bile ac ids are unable to perform their normal func tion of binding with the lipid produc ts in the food, allowing the fats to be absorbed in the form of forming mic elles. The enterohepatic c irc ulation of bile ac ids is therefore broken, c holesterol and triglyc erides in the diet are absorbed muc h less readily. Additionally, bec ause bile ac ids are not reabsorbed and returned to the liver, more c holesterol must be metabolized into bile ac ids within the liver in order to maintain the sec retion of bile ac ids into the duodenum. These ac tivities c ombine to c ause a mild to moderate reduc tion in the blood c holesterol level. Unfortunately their use is often ac c ompanied by gastrointestinal side-effec ts and they are rather diffic ult to take on a regular three-times-a-day basis. Their use has therefore dec lined somewhat in rec ent years. An example is given in the following table. 
Statins
The main ac tivity of a statin is to inhibit the enzyme hydroxymethyl CoA reduc tase. This enzyme is, of c ourse, an integral part of the c holesterol synthetic mec hanism. Inhibition of its ac tivity reduc es the amount of c holesterol that c an be synthesis within the liver. Statins, of whic h there are now quite a number of c ompeting varieties, are therefore partic ularly good at reduc ing the level of blood c holesterol. They are also responsible for reduc ing the level of LDL c holesterol and triglyc erides, but to a lesser extent and probably as a sec ondary ac tion to the inhibition of c holesterol synthesis. 
Fibrates
The mec hanism of ac tion of the fibrate drugs is not quite as c lear as that of statins and resins. Nevertheless, a list of ac tions for whic h they seem to be responsible has been drawn up: -
• a) a signific ant lowering of plasma triglyc eride levels ( by 2 0 -4 0 %) . This is mainly via the stimulation of the ac tivity of lipoprotein lipase whic h is responsible for hydrolysing the trigyc eride-ric h Very Low Density Lipoproteins ( VLDL) frac tion.
• b) a modest rise in HDL-c holesterol ( approx. 1 0 %) • c ) variable c hange in LDL-c holesterol -most fibrates c ause a small ( approx. 1 0 %) fall, but at least one fibrate ( Gemfibrozil) c an sometimes c ause a rise in LDLc holesterol
• d) a possible inhibition of fatty-ac id synthesis and inc rease in fatty-ac id breakdown.
• e) reduc tion in platelet reac tivity and aggregation. This ac tion thus reduc es the likelihood of platelet c lumping and henc e of c lot formation and vessel bloc kage.
Work in rec ent years has indic ated fibrates influenc e multiple steps in the metabolism of lipids and lipoproteins by modifying the transc ription of a variety of genes through ac tivation of the peroxisomal proliferator ac tivated rec eptor ( PPAR) mec hanism ( 3 , 4 ) ) .
Fibrates currently available include: -
In summary then there is good evidenc e to support the views that treatment of hyperc holesterolaemia and hypertriglyc eridaemia c an c ause reduc tion in levels of these lipids and their assoc iated harmful lipoproteins and that suc h a reduc tion will result in a signific ant dec rease in the c ardiovasc ular risk of the patient. An example of treatment with a fibrate is given in the following Recommended literature:
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